CD152 antibody | BNI3
A microtiter plate was coated overnight with Mouse Anti-Human CD152 Antibody, clone BNI3 (MCA1724) at a concentration of 1 µg/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of abatacept. Detection was performed using HRP conjugated Human Anti-Abatacept Antibody, clone AbD37058ia (HCA335) at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements. HRP conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit (LNK002P).
A microtiter plate was coated overnight with abatacept at a concentration of 1 µg/ml. After washing and blocking with PBST + 5% BSA, PBST with 10% human serum was added spiked with increasing concentrations of Human Anti-Abatacept Antibody, clone AbD37058ia (HCA335, black), clone AbD37065ia (HCA336, red) or Mouse Anti-Human CD152 (MCA1724, blue). Detection was performed using HRP conjugated abatacept followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements. HRP conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit (LNK002P).
Mouse anti Human CD152 antibody, clone BNI3 recognizes human CD152, also known as CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4), an inhibitory receptor and negative regulator of T-cell responses. CD152 is a single pass type 1 transmembrane protein belonging to the immunoglobulin superfamily containing a single Ig-v-like domain in the extracellular region.
CD152 along with CD28 binds to the co-stimulatory molecules CD80 and CD86 (Azuma et al. 1993).
Mouse anti human CD152 antibody, clone BNI3 is able to block ligand binding on the Raji B-cell line (Steiner et al. 2001) and blocks binding of an alternative clone, BNI8 to CTLA-4/Ig in ELISA. Mouse anti Human CD152 antibody, clone BNI3 binds to the same epitope as classified anti CTLA-4 clones 11D4 and 10A8 (Wang et al. In: Leukocyte typing VI 1997 Garland Publishing Inc. pp97-98, Bull World Health Organ. 1997).
The cytoplasmic domain of CD152 contains a critical tyrosine at residue 201 phosphorylated by Janus Kinase 2 which subsequently controls surface expression through regulation of CD152 interaction with AP-2 (Shiratori et al. 1997, Chikuma et al. 2000). CD152 is expressed primarily as an intracellular antigen with transport to the cell surface under tight regulation of several molecules including Trim, PLD and TIRC7, CD152 also demonstrates rapid internalization once expressed at the cell surface (Valk et al. 2008). CD152 plays a significant role in maintaining tolerance to self antigens and defects in CD152 presentation and expression has been implicated in a number of autoimmune diseases (Romo-Tena et al. 2013).
This antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free fusion protein drug abatacept. It is recommended as the capture reagent, paired with human anti abatacept antibody HCA335 as the detection antibody.
Abatacept (Orencia) is a recombinant fusion protein consisting of the extra-cellular domain of human CTLA-4, fused to the modified Fc (hinge, CH2, and CH3 domains) portion of human IgG1.
CD152 along with CD28 binds to the co-stimulatory molecules CD80 and CD86 (Azuma et al. 1993).
Mouse anti human CD152 antibody, clone BNI3 is able to block ligand binding on the Raji B-cell line (Steiner et al. 2001) and blocks binding of an alternative clone, BNI8 to CTLA-4/Ig in ELISA. Mouse anti Human CD152 antibody, clone BNI3 binds to the same epitope as classified anti CTLA-4 clones 11D4 and 10A8 (Wang et al. In: Leukocyte typing VI 1997 Garland Publishing Inc. pp97-98, Bull World Health Organ. 1997).
The cytoplasmic domain of CD152 contains a critical tyrosine at residue 201 phosphorylated by Janus Kinase 2 which subsequently controls surface expression through regulation of CD152 interaction with AP-2 (Shiratori et al. 1997, Chikuma et al. 2000). CD152 is expressed primarily as an intracellular antigen with transport to the cell surface under tight regulation of several molecules including Trim, PLD and TIRC7, CD152 also demonstrates rapid internalization once expressed at the cell surface (Valk et al. 2008). CD152 plays a significant role in maintaining tolerance to self antigens and defects in CD152 presentation and expression has been implicated in a number of autoimmune diseases (Romo-Tena et al. 2013).
This antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free fusion protein drug abatacept. It is recommended as the capture reagent, paired with human anti abatacept antibody HCA335 as the detection antibody.
Abatacept (Orencia) is a recombinant fusion protein consisting of the extra-cellular domain of human CTLA-4, fused to the modified Fc (hinge, CH2, and CH3 domains) portion of human IgG1.
Product Details
- Target Species
- Human
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - liquid
- Preparation
- Purified by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- <0.1% Sodium Azide (NaN3)
- Preservative Stabilisers
- 0.1% Sodium Azide (NaN3)
2% Bovine Serum Albumin - Immunogen
- Human CTLA-4/human IgG heavy chain fusion protein.
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells of the mouse P3/X63-Ag8.653 myeloma cell line.
Storage Information
- Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC.
DO NOT FREEZE
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- UniProt
- P16410
- Entrez Gene
- CTLA4
- GO Terms
- GO:0005887 integral to plasma membrane
- GO:0005794 Golgi apparatus
- GO:0006955 immune response
- GO:0006974 response to DNA damage stimulus
- GO:0009897 external side of plasma membrane
- GO:0030889 negative regulation of B cell proliferation
- GO:0031295 T cell costimulation
- GO:0043065 positive regulation of apoptosis
- GO:0045334 clathrin-coated endocytic vesicle
- GO:0045590 negative regulation of regulatory T cell differentiation
- GO:0048471 perinuclear region of cytoplasm
- GO:0050853 B cell receptor signaling pathway
- Acknowledgements
- Orencia is a trademark of Bristol-Myers Squibb Company
- Regulatory
- For research purposes only
Applications of CD152 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| Flow Cytometry 1 | Neat | 1/10 | |
| Immunofluorescence | |||
| Immunohistology - Frozen 2 | 5ug/ml | 50ug/ml | |
| Immunohistology - Paraffin | |||
| Immunoprecipitation | |||
| Flow Cytometry 1 | Neat |
- 1Membrane permeabilization is required for this application. Bio-Rad recommend the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 2The epitope recognised by this antibody is reported to be sensitive to formaldehyde fixation and tissue processing. Bio-Rad recommends the use of acetone fixation for frozen sections.
- 1 Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
- Flow Cytometry
- Use 20ul of the suggested working dilution to label 5x105 cells in 100ul.
- ELISA
- Clone BNI3 can be used as the capture antibody in a bridging ELISA with HCA335 as the detection antibody.
Protocol: PK bridging ELISA
Protocol: ADA bridging ELISA
Copyright © 2021 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse IgG2a Negative Control | MCA929 | F | 100 Tests |
|
|
| Mouse IgG2a Negative Control:RPE | MCA929PE | F | 100 Tests |
|
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Human anti Abatacept | HCA335 | E | 0.1 mg |
|
|
| Human anti Abatacept | HCA336 | E | 0.1 mg |
|
|
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test |
Product Specific References
References for CD152 antibody
-
Linsley, P.S. et al. (1992) Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
J Exp Med. 176 (6): 1595-604. -
Kuiper, H.M. et al. (1995) Activated T cells can induce high levels of CTLA-4 expression on B cells.
J Immunol. 155 (4): 1776-83. -
Castan, J. et al. (1997) Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues.
Immunology. 90 (2): 265-71. -
Lee, C.C. et al. (2009) The regulatory function of umbilical cord blood CD4(+) CD25(+) T cells stimulated with anti-CD3/anti-CD28 and exogenous interleukin (IL)-2 or IL-15.
Pediatr Allergy Immunol. 20 (7): 624-32. -
Pistillo, M.P. et al. (2003) CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells.
Blood. 101: 202-9. -
Tan, P.H. et al. (2005) Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression.
Blood. 106: 2936-43. -
Steiner, K. et al. (2001) Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis.
Clin Exp Immunol. 126: 143-50. -
Lu, C.H. et al. (2016) DNA Methyltransferase Inhibitor Promotes Human CD4+CD25hFOXP3+ Regulatory T Lymphocyte Induction under Suboptimal TCR Stimulation.
Front Immunol. 7: 488. -
Steiner, K. et al. (1999) Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection.
Clin Exp Immunol. 115 (3): 451-7. -
Ward, F.J. et al. (2013) The soluble isoform of CTLA-4 as a regulator of T-cell responses.
Eur J Immunol. 43 (5): 1274-85.
Further Reading
-
Chin, L.T. et al. (2008) Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases.
Chang Gung Med J. 31: 1-15.
Fluorescent Spectraviewer
Watch the Tool Tutorial Video ▸How to Use the Spectraviewer
Watch the Tool Tutorial Video ▸- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra
